ArticleClinical case reports2024

Case report: Emerging BRCA mutation confers benefit from olaparib after chemotherapy intolerance in advanced triple-negative breast cancer.

Xia-Bo Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.